CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older Association of Cardiovascular Disease With Respiratory Disease The Prevalence of Myocardial Bridging Associated with Coronary Endothelial Dysfunction in Patients with Chest Pain and Non-Obstructive Coronary Artery Disease Mediterranean Diet and the Association Between Air Pollution and Cardiovascular Disease Mortality Risk In-stent neoatherosclerosis: a final common pathway of late stent failure Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Minimizing Permanent Pacemaker Following Repositionable Self-Expanding Transcatheter Aortic Valve Replacement Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome? Bioprosthetic valve oversizing is associated with increased risk of valve thrombosis following TAVR
|<<... 87 88 89 90 91 92 93 ...>>|

Review ArticleVolume 74, Issue 5, August 2019

JOURNAL：J Am Coll Cardiol. Article Link

From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)

DP Leong, JJV McMurray, PG Joseph et al. Keywords: ACE-I; ARB; ARNI; coronary disease; heart failure

ABSTRACT

The pharmacological inhibition of the renin-angiotensin-aldosterone system as a therapeutic strategy is one of the most significant advances in the treatment and prevention of cardiovascular disease in heart failure with reduced ejection fraction and in coronary artery disease. Recently, the addition of neprilysin inhibition to angiotensin receptor blockade has been shown to be even more effective than angiotensin-converting enzyme inhibition alone in heart failure with reduced ejection fraction, marking an important new milestone in heart failure treatment. This review summarizes the major trials that have informed the clinical role of inhibition of the renin-angiotensin-aldosterone and neprilysin pathways, as well as the limitations of these strategies.

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top